Related Experiment Video
Updated: Jun 24, 2025
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
Published on: August 18, 2010
Targeting pediatric solid tumors in the new era of RNA therapeutics
Parunya Chaiyawat1, Surasak Sangkhathat2, Wararat Chiangjong3
1Musculoskeletal Science and Translational Research Center, Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Center of Multidisciplinary Technology for Advanced Medicine (CMUTEAM), Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Extracellular Vesicle Working Group, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
Abstract:
Despite substantial progress in pediatric cancer treatment, poor prognosis remained for patients with recurrent or metastatic disease, given the limitations of approved targeted treatments and immunotherapies. RNA therapeutics offer significant potential for addressing a broad spectrum of diseases, including cancer. Advances in manufacturing and delivery systems are paving the way for the rapid development of therapeutic RNAs for clinical applications. This review summarizes therapeutic RNA classifications and the mechanisms of action, highlighting their potential in manipulating major cancer-related pathways and biological effects. We also focus on the pre-clinical investigation of RNA molecules with efficient delivery systems for their therapeutic potential targeting pediatric solid tumors.
Insights
RNA therapeutics show promise for treating pediatric cancers, especially recurrent or metastatic cases. Advances in delivery systems enhance their potential to target cancer pathways effectively.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Pediatric cancer treatment faces challenges with recurrent/metastatic disease, limited by current therapies.
- RNA therapeutics present a promising avenue for diverse diseases, including cancer.
- Manufacturing and delivery advancements accelerate clinical applications of therapeutic RNAs.
Purpose of the Study:
- To review therapeutic RNA classifications and mechanisms.
- To highlight RNA's potential in modulating cancer pathways.
- To focus on preclinical RNA investigations for pediatric solid tumors.
Main Methods:
- Literature review of RNA therapeutic classifications.
- Analysis of RNA mechanisms of action in cancer.
- Examination of preclinical studies on RNA delivery for pediatric solid tumors.
Main Results:
- Therapeutic RNAs can target key cancer-related pathways.
- Efficient delivery systems are crucial for RNA efficacy.
- Preclinical data suggest potential for pediatric solid tumor treatment.
Conclusions:
- RNA therapeutics offer a novel strategy for pediatric cancers.
- Further research into delivery systems is vital for clinical translation.
- RNA-based treatments hold significant promise for improving outcomes in pediatric oncology.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:15Experimental RNAi
02:30siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...